dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Alcázar Navarrete, Bernardino |
dc.contributor.author | García-Rio, Francisco |
dc.contributor.author | Sánchez, Guadalupe |
dc.contributor.author | Mariscal, Esther |
dc.contributor.author | García, Andrea |
dc.contributor.author | Cuesta, Maribel |
dc.contributor.author | Miravitlles Fernández, Marc |
dc.date.accessioned | 2022-03-23T11:58:14Z |
dc.date.available | 2022-03-23T11:58:14Z |
dc.date.issued | 2021-07-21 |
dc.identifier.citation | Alcázar-Navarrete B, García-Rio F, Sánchez G, Mariscal E, García A, Cuesta M, et al. Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain. Int J Chron Obstruct Pulmon Dis. 2021 Jul 21;16:2149–61. |
dc.identifier.issn | 1178-2005 |
dc.identifier.uri | https://hdl.handle.net/11351/7251 |
dc.description | MPOC; Eosinòfils; Teràpia triple |
dc.description.sponsorship | This study was funded by GlaxoSmithKline (study 206555). |
dc.language.iso | eng |
dc.publisher | Dove Medical Press |
dc.relation.ispartofseries | International Journal of Chronic Obstructive Pulmonary Disease;16 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Malalties obstructives - Tractament |
dc.subject | Teràpia respiratòria |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Retrospective Studies |
dc.subject.mesh | Drug Therapy, Combination |
dc.title | Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/COPD.S310319 |
dc.subject.decs | enfermedad pulmonar obstructiva crónica |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | estudios retrospectivos |
dc.subject.decs | farmacoterapia combinada |
dc.relation.publishversion | https://doi.org/10.2147/COPD.S310319 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Alcázar-Navarrete B] Respiratory Department. Hospital Universitario Virgen de las Nieves, Granada, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. [García-Rio F] CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. [Sánchez G] Medical Department, GSK, Madrid, Spain. [Mariscal E, García A] Market Access Department, GSK, Madrid, Spain. [Cuesta M] Oblikue Consulting, Barcelona, Spain. [Miravitlles M] CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 34321874 |
dc.identifier.wos | 000677620400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |